(Q36593747)

15 August 2017

1 reference

title

Immune resistance orchestrated by the tumor microenvironment (English)

1 reference

15 August 2017

1

Thomas F Gajewski

1 reference

15 August 2017

3

Christian Blank

1 reference

15 August 2017

Yuru Meng

2

1 reference

15 August 2017

Ian Brown

4

1 reference

15 August 2017

Aalok Kacha

5

1 reference

15 August 2017

Justin Kline

6

1 reference

15 August 2017

Helena Harlin

7

1 reference

15 August 2017

1 October 2006

1 reference

15 August 2017

Immunological Reviews

1 reference

15 August 2017

213

1 reference

15 August 2017

131-145

1 reference

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans

15 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

ICAM-1 contributes to but is not essential for tumor antigen cross-priming and CD8+ T cell-mediated tumor rejection in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Genetic changes occurring in established tumors rapidly stimulate new antibody responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Autoantibody signatures in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Paraneoplastic neurological degenerations: keys to tumour immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Tumor progression, early diagnosis and prognosis of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

CXC chemokine ligand 12 (stromal cell-derived factor 1 alpha) and CXCR4-dependent migration of CTLs toward melanoma cells in organotypic culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1/CXCL12 induce tumor-specific T cell chemorepulsion and escape from immune control

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Strong expression of the lymphoattractant C-X-C chemokine Mig is associated with heavy infiltration of T cells in human malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

T-Cell Function and Migration — Two Sides of the Same Coin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Regulatory T cells, tumour immunity and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Defective adhesion in tumor infiltrating CD8+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Induction of cytotoxic granules in human memory CD8+ T cell subsets requires cell cycle progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Immune suppression in the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Predominance of a type 2 intratumoural immune response in fresh tumour-infiltrating lymphocytes from human gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Control of T lymphocyte signal transduction through clonal anergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

B cells inhibit induction of T cell-dependent tumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Inhibition of tumor growth by elimination of granulocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Negative regulation of T-cell function by PD-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

B7x: a widely expressed B7 family member that inhibits T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

B7-H4, a molecule of the B7 family, negatively regulates T cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

T cell apoptosis by tryptophan catabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Tolerance, DCs and tryptophan: much ado about IDO

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Mammary tumor latency is increased in mice lacking the inducible nitric oxide synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Analysis of the mechanisms of human cytotoxic T lymphocyte response inhibition by NO.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Metabolic mechanisms of tumor resistance to T cell effector function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Glucose availability regulates IFN-gamma production and p70S6 kinase activation in CD8+ effector T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Expression of interleukin 10 in human melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Interleukin 10 (IL-10): an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

TGF-beta regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Interferon-gamma and cancer immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Role of nuclear factor-kappa B in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Bcl-2 and bcl-xL antisense oligonucleotides induce apoptosis in melanoma cells of different clinical stages

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

PI3K mediates protection against TRAIL-induced apoptosis in primary human melanocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

How melanoma cells evade trail-induced apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Downregulation of survivin expression enhances sensitivity of cultured uveal melanoma cells to cisplatin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Immune interactions at the maternal-fetal interface

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

B7 family molecules are favorably positioned at the human maternal-fetal interface

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Tryptophan catabolism prevents maternal T cells from activating lethal anti-fetal immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

CD4+CD25+ regulatory/suppressor T cells prevent allogeneic fetus rejection in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Regulatory T cells induce a privileged tolerant microenvironment at the fetal-maternal interface

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Structure, chromosomal localization, and expression of 12 genes of the MAGE family

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Roles of activated Src and Stat3 signaling in melanoma tumor cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

The hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Effects of overexpression of CXCL10 (cytokine-responsive gene-2) on MA-10 mouse Leydig tumor cell steroidogenesis and proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

VEGF as a mediator of tumor-associated immunodeficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Bystander elimination of antigen loss variants in established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Synergy between tumor immunotherapy and antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Fibroblast activation protein-alpha and dipeptidyl peptidase IV (CD26): cell-surface proteases that activate cell signaling and are potential targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00442.X

10.1111/J.1600-065X.2006.00442.X

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference